Dr. Riedl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065Phone+1 212-639-2000
Education & Training
Memorial Sloan Kettering Cancer CenterResidency, Nuclear Medicine, 2012 - 2014
University of Vienna Faculty of MedicineClass of 2001
Certifications & Licensure
NY State Medical License 2015 - 2027
NJ State Medical License 2017 - 2025- American Board of Nuclear Medicine Nuclear Medicine
- American Board of Radiology Diagnostic Radiology
Awards, Honors, & Recognition
- Many
Clinical Trials
- Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer Start of enrollment: 2019 Aug 09
Publications & Presentations
PubMed
- 81 citationsLymph Node Imaging in Patients with Primary Breast Cancer: Concurrent Diagnostic Tools.Maria Adele Marino, Daly Avendano, Pedro Zapata, Christopher C Riedl, Katja Pinker
The Oncologist. 2020-02-01 - 81 citationsHead-to-Head Evaluation of 18F-FES and 18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer.Gary A. Ulaner, Komal Jhaveri, Sarat Chandarlapaty, Vaios Hatzoglou, Christopher C. Riedl
Journal of Nuclear Medicine. 2021-03-01 - 91 citationsComparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal CarcinomaMolly P Hogan, Debra A. Goldman, Brittany Z. Dashevsky, Christopher C. Riedl, Mithat Gonen
Journal of Nuclear Medicine. 2015-11-01
Press Mentions
FDG-PET/CT Shows Promise for Breast Cancer Patients Younger Than 40October 1st, 2014
Other Languages
- German, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
